Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Marabelle

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 5, 2017
Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapyP Pradere, J M Michot, S Champiat, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|December 31, 2011
Clear cell ependymoma with trisomy 19 developing bone metastasesM Payet, C Conter, F Labrousse, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 23, 2017
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatmentH Picchi, C Mateus, C Chouaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesM Smoragiewicz, J Bogaerts, E Calvo, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2017
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteriaM Tazdait, L Mezquita, J Lahmar, et al.
Immuno-Oncology Technology|January 8, 2026
Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)N Alshatti, F Lemonnier, E Bachy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case reportJ-M Michot, L Albiges, N Chaput, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2022
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studiesV Moreno, E Calvo, M R Middleton, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumoursH Herin, S Aspeslagh, E Castanon, et al.
Gynecologic Oncology|July 14, 2022
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 studyD M O'Malley, G M Bariani, P A Cassier, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|March 5, 2017
Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapyP Pradere, J M Michot, S Champiat, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|December 31, 2011
Clear cell ependymoma with trisomy 19 developing bone metastasesM Payet, C Conter, F Labrousse, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 23, 2017
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatmentH Picchi, C Mateus, C Chouaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesM Smoragiewicz, J Bogaerts, E Calvo, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2017
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteriaM Tazdait, L Mezquita, J Lahmar, et al.
Immuno-Oncology Technology|January 8, 2026
Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)N Alshatti, F Lemonnier, E Bachy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case reportJ-M Michot, L Albiges, N Chaput, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2022
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studiesV Moreno, E Calvo, M R Middleton, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumoursH Herin, S Aspeslagh, E Castanon, et al.
Gynecologic Oncology|July 14, 2022
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 studyD M O'Malley, G M Bariani, P A Cassier, et al.
Pageof 5